ABL Bio Inc. (KOSDAQ:298380)
South Korea
· Delayed Price · Currency is KRW 190,300
+13,200 (7.45%)
At close: Mar 6, 2026
ABL Bio Company Description
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor.
It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor.
ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.
ABL Bio Inc.
| Country | South Korea |
| Founded | 2016 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Sang Hoon Lee |
Contact Details
Address: 456 Bongeunsa-ro Seoul, 06153 South Korea | |
| Phone | 82 2 3456 7300 |
| Website | ablbio.com |
Stock Details
| Ticker Symbol | 298380 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7298380007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sang Hoon Lee | Chief Executive Officer |
| Jaecheon Lee | Chief Financial Officer |
| Jung Dae Kim | Chief Operating Officer |